News on Optimer Pharmaceuticals from BioPortfolio.com http://www.BioPortfolio.com Consolidated Optimer Pharmaceuticals news from BioPortfolio.com Tue, 09 Feb 2010 21:26:42 GMT en Form SC 13G/A OPTIMER PHARMACEUTICALS Filed by: PROQUEST INVESTMENTS II LPhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037320&HITNO=0&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037320&THISHREF=http://c.moreover.com/click/here.pl%3fz2537027390%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037320&HITNO=0&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037320&THISHREF=http://c.moreover.com/click/here.pl%3fz2537027390%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: Optimer gets positive results from 2nd pivotal phase-3 study of fidaxomicin in clostridum difficile infectionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034670&HITNO=1&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034670&THISHREF=http://c.moreover.com/click/here.pl%3fz2535915545%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034670&HITNO=1&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034670&THISHREF=http://c.moreover.com/click/here.pl%3fz2535915545%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaBiz: Optimer trial results lead to takeover talkshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030656&HITNO=2&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030656&THISHREF=http://c.moreover.com/click/here.pl%3fz2533748602%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4030656&HITNO=2&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4030656&THISHREF=http://c.moreover.com/click/here.pl%3fz2533748602%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFierceBiotech: Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Closhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026069&HITNO=3&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026069&THISHREF=http://c.moreover.com/click/here.pl%3fz2530334491%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4026069&HITNO=3&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4026069&THISHREF=http://c.moreover.com/click/here.pl%3fz2530334491%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Optimer Pharma Rises On Fidaxomicin Study Datahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024531&HITNO=4&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024531&THISHREF=http://c.moreover.com/click/here.pl%3fz2528965192%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024531&HITNO=4&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024531&THISHREF=http://c.moreover.com/click/here.pl%3fz2528965192%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Channel: Optimer Pharma Rises On Fidaxomicin Study Datahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024228&HITNO=5&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024228&THISHREF=http://c.moreover.com/click/here.pl%3fz2528720871%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024228&HITNO=5&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024228&THISHREF=http://c.moreover.com/click/here.pl%3fz2528720871%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBoston Channel: Optimer reports positive results from second Phase III study of antibiotic drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023922&HITNO=6&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023922&THISHREF=http://c.moreover.com/click/here.pl%3fz2528488693%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023922&HITNO=6&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023922&THISHREF=http://c.moreover.com/click/here.pl%3fz2528488693%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Optimer Reports Positive Phase III Data for Antibiotic against C. Difficilehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024048&HITNO=7&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024048&THISHREF=http://c.moreover.com/click/here.pl%3fz2528602100%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4024048&HITNO=7&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4024048&THISHREF=http://c.moreover.com/click/here.pl%3fz2528602100%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Clostridium Difficile Infectionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017971&HITNO=8&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017971&THISHREF=http://c.moreover.com/click/here.pl%3fz2525404604%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4017971&HITNO=8&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4017971&THISHREF=http://c.moreover.com/click/here.pl%3fz2525404604%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Optimer Pharmaceuticals Product Shows Promise Against Competitorhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022438&HITNO=9&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022438&THISHREF=http://c.moreover.com/click/here.pl%3fz2527665594%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022438&HITNO=9&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022438&THISHREF=http://c.moreover.com/click/here.pl%3fz2527665594%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSan Diego Business Journal: Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Closhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019342&HITNO=10&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019342&THISHREF=http://c.moreover.com/click/here.pl%3fz2526234474%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019342&HITNO=10&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019342&THISHREF=http://c.moreover.com/click/here.pl%3fz2526234474%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patientshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019030&HITNO=11&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019030&THISHREF=http://c.moreover.com/click/here.pl%3fz2526075820%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019030&HITNO=11&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019030&THISHREF=http://c.moreover.com/click/here.pl%3fz2526075820%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Optimer Pharmas Antibiotic Succeeds in Late-Stage Trial Againhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023871&HITNO=12&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023871&THISHREF=http://c.moreover.com/click/here.pl%3fz2528449308%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023871&HITNO=12&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023871&THISHREF=http://c.moreover.com/click/here.pl%3fz2528449308%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFDA News: Optimer's fidaxomicin is as effective as Vancocin in late-stage studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022329&HITNO=13&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022329&THISHREF=http://c.moreover.com/click/here.pl%3fz2527608590%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022329&HITNO=13&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022329&THISHREF=http://c.moreover.com/click/here.pl%3fz2527608590%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Optimer Pharma rises on fidaxomicin study datahttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022376&HITNO=14&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022376&THISHREF=http://c.moreover.com/click/here.pl%3fz2527632858%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022376&HITNO=14&MSIZE=99&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Optimer%20Pharmaceuticals&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022376&THISHREF=http://c.moreover.com/click/here.pl%3fz2527632858%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: